Made In NC, Novo Nordisk's Wegovy Pill Is Available Now

The FDA has approved the first oral GLP-1 treatment for obesity in the U.S.—Novo Nordisk’s Wegovy pill. This once-daily medication represents a major advancement in weight management, offering an alternative to injectable therapies. Clinical trial results show significant efficacy: patients taking the pill alongside diet and exercise achieved an average weight loss of about 17%, compared to 3% with a placebo. Beyond weight management, the Wegovy pill is indicated to lower the risk of major cardiovascular events for overweight or obese adults with existing heart disease. With manufacturing underway and availability expected in early January, this new option provides greater flexibility for patients and healthcare providers.

Learn more about how this milestone could reshape obesity treatment and expand access to proven GLP-1 therapy.